<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414476</url>
  </required_header>
  <id_info>
    <org_study_id>STRESSCARBONYL1</org_study_id>
    <nct_id>NCT03414476</nct_id>
  </id_info>
  <brief_title>Demonstration of Carbonyl Stress on Hair Follicles</brief_title>
  <official_title>Demonstration of the Presence of Carbonyl Stress in the Hair Follicles of Women With Reactive Hair Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Dermo Cosmetique</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Dermo Cosmetique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigator will try to highlight the presence of carbonyl compounds in&#xD;
      the hair follicles of women with telogen effluvium (ET) linked to stress of various origins&#xD;
      (fatigue, infectious diseases, emotional stress ...).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the cutaneous level, oxidative stress induces the formation of carbonyl compounds which,&#xD;
      by binding to proteins, produce nonfunctional adducts inducing cutaneous aging. Is this&#xD;
      mechanism, called &quot;Carbonyl stress&quot;, also present in the scalp and can it be one of the&#xD;
      mechanisms involved in the occurrence of reactive hair loss ? To demonstrate this, samples of&#xD;
      hair follicles are made. The proteins are extracted from the samples and then assayed. The&#xD;
      oxidized (carbonyl) proteins are labeled with specific fluorescent probes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Actual">June 25, 2018</completion_date>
  <primary_completion_date type="Actual">June 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1 group of women with effluvium télogène&#xD;
1 group of women without effluvium télogène</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Monocentric, Exploratory study, open, comparative, in parallel groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Biological evaluation</measure>
    <time_frame>Visit 1- Day 1</time_frame>
    <description>Evaluation of the quantity of carbonyl compounds measured in the hair follicles taken from the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>Visit 1- Day 1</time_frame>
    <description>Adverse events evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Effluvium; Telogen</condition>
  <arm_group>
    <arm_group_label>ET group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sampling : Hair follicles sampling on the scalp in women with Telogene Effluvium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sampling: Hair follicles sampling on the scalp in women without Telogene Effluvium</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hair follicles sampling</intervention_name>
    <description>The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>ET group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria related to the Population :&#xD;
&#xD;
          -  Women aged from 18 to 40 ans (included)&#xD;
&#xD;
          -  Phototype I à IV included, according to Fitzpatrick Classification&#xD;
&#xD;
          -  Hair length 5 cm on the sampling area (centro-parietal part)&#xD;
&#xD;
          -  Last shampoo at least 2 days before the inclusion visit, without application of&#xD;
             styling product, care or water between this last shampoo and the inclusion&#xD;
&#xD;
          -  Informed consent signature&#xD;
&#xD;
        Criteria related to the studied condition:&#xD;
&#xD;
          -  ET group: hair loss related to various etiologies evaluated by a questionnaire&#xD;
             according to the investigator's opinion and positive pull test (at least 3 hair&#xD;
             collected per lock of 50 to 60 hair) AND&#xD;
&#xD;
          -  Control group : no hair loss, evaluated by the questionnaire and negative pull test&#xD;
             (less than 3 hair collected per lock of 50 to 60 hair)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Criteria related to Population :&#xD;
&#xD;
          -  Menopause&#xD;
&#xD;
          -  Pregnancy, breastfeeding, childbirth for less than 6 months&#xD;
&#xD;
        Criteria related to Pathology :&#xD;
&#xD;
        For both groups:&#xD;
&#xD;
          -  Alopecia causing hair loss on the upper part of the scalp&#xD;
&#xD;
          -  Dermatological pathology or evolving cutaneous lesion in the scalp&#xD;
&#xD;
          -  Control group only:&#xD;
&#xD;
          -  Chronic unstabilized condition&#xD;
&#xD;
          -  Acute evolving pathology&#xD;
&#xD;
        Criteria related to theTreatments :&#xD;
&#xD;
        For both groups:&#xD;
&#xD;
          -  Use for at least 1 month of Minoxidil, Aminexil in the 3 months before inclusion or&#xD;
             ongoing&#xD;
&#xD;
          -  Systemic treatment affecting hair growth&#xD;
&#xD;
          -  Any treatment or dietary supplement for antioxidant or capillary&#xD;
&#xD;
        Control group only:&#xD;
&#xD;
          -  Treatment of general thyroid disorders initiated or modified for less than 3 months&#xD;
             prior to inclusion&#xD;
&#xD;
          -  Treatment of anemia if started less than 3 months before inclusion&#xD;
&#xD;
          -  General treatment initiated or modified for less than 3 months prior to inclusion in&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine SAINT MARTORY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unaffiliate</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Pharmacologie Clinique Appliquée à la Dermatologie</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de santé SABOURAUD</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INTERTEK France</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche sur la Peau</name>
      <address>
        <city>Toulouse</city>
        <zip>31025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire Dermscan</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Proof of concept study, with confidential data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

